Skip to main content
Premium Trial:

Request an Annual Quote

Luminex Completes EraGen Purchase for $34M

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Luminex said after the close of the market on Monday that it has completed its $34 million all-cash purchase of EraGen Biosciences.

Luminex said the acquisition of the Madison, Wis.-based molecular diagnostics firm would add between $5 million and $7 million in revenues to Luminex in 2011. The deal is expected to be dilutive to 2011 earnings and accretive to 2012 earnings on a GAAP basis.

Luminex said last week when the deal was announced that EraGen is expected to remain headquartered in Madison.

EraGen develops molecular diagnostic technologies for infectious disease and genetic applications. Its products include its FDA-cleared MultiCode-RTx Herpes Simplex Virus 1&2 kit for detecting and typing HSV-1 or HSV-2 from vaginal lesion swab specimens.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more